Phase I/II study of capmatinib plus erlotinib in patients with MET-positive non–small-cell lung cancer

CE McCoach, A Yu, DR Gandara, JW Riess… - JCO precision …, 2021 - ascopubs.org
PURPOSE MET dysregulation is an oncogenic driver in non–small-cell lung cancer
(NSCLC), as well as a mechanism of TKI (tyrosine kinase inhibitor) resistance in patients …
被引用次数：23 相关文章

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer

CE McCoach, A Yu, DR Gandara, JW Riess… - JCO Precision …, 2021 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> PURPOSE</jats: title>< jats: p> MET dysregulation is an
oncogenic driver in non–small-cell lung cancer (NSCLC), as well as a mechanism of TKI …

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer.

CE McCoach, A Yu, DR Gandara, JW Riess… - JCO Precision …, 2021 - europepmc.org
PURPOSE MET dysregulation is an oncogenic driver in non–small-cell lung cancer
(NSCLC), as well as a mechanism of TKI (tyrosine kinase inhibitor) resistance in patients …

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer

CE McCoach, A Yu, DR Gandara… - JCO precision …, 2021 - pubmed.ncbi.nlm.nih.gov
Purpose MET dysregulation is an oncogenic driver in non-small-cell lung cancer (NSCLC),
as well as a mechanism of TKI (tyrosine kinase inhibitor) resistance in patients with …
[HTML] nih.gov

[HTML][HTML] Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer

CE McCoach, A Yu, DR Gandara, JW Riess… - JCO Precision …, 2021 - ncbi.nlm.nih.gov
PURPOSE MET dysregulation is an oncogenic driver in non–small-cell lung cancer
(NSCLC), as well as a mechanism of TKI (tyrosine kinase inhibitor) resistance in patients …

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer.

CE McCoach, A Yu, DR Gandara, JW Riess… - JCO precision …, 2021 - escholarship.org
MET dysregulation is an oncogenic driver in non-small-cell lung cancer (NSCLC), as well as
a mechanism of TKI (tyrosine kinase inhibitor) resistance in patients with epidermal growth …